Efficacy and safety of triple therapy with recombinant interleukin-1β, recombinant interferon-α and ribavirin in patients with chronic hepatitis C, genotype 1 infection, the non-responders to previous treatment with interferon and ribavirin
To assess the efficacy and safety of an experimental course of antiviral therapy with recombinant IL-1β in combination with recombinant interferon-α2b and ribavirin in patients with chronic hepatitis C infected with genotype 1 hepatitis C virus in lacking the virologic response to previous dual ther...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Journal Infectology
2014-09-01
|
| Series: | Журнал инфектологии |
| Subjects: | |
| Online Access: | https://journal.niidi.ru/jofin/article/view/137 |
| _version_ | 1797695526289801216 |
|---|---|
| author | Yu. V. Lobzin K. V. Zhdanov A. S. Simbirtsev A. A. Yakovlev S. N. Kizhlo V. H. Fazilov S. N. Zharov M. F. Lebedev |
| author_facet | Yu. V. Lobzin K. V. Zhdanov A. S. Simbirtsev A. A. Yakovlev S. N. Kizhlo V. H. Fazilov S. N. Zharov M. F. Lebedev |
| author_sort | Yu. V. Lobzin |
| collection | DOAJ |
| description | To assess the efficacy and safety of an experimental course of antiviral therapy with recombinant IL-1β in combination with recombinant interferon-α2b and ribavirin in patients with chronic hepatitis C infected with genotype 1 hepatitis C virus in lacking the virologic response to previous dual therapy pegIFN-α or standard IFN-α and ribavirin has been formed by a group of 50 patients. All patients were treated with recombinant IL-1β – 10 subcutaneous injection at a dose of 0.005 mg/kg every other day, the course of 3 weeks, with 5 courses, recombinant IFN-α2b – subcutaneous injections of 3 million IU every other day for 48 weeks. Ribavirin 1000–1200 mg per day (depending on body weight) for 48 weeks. The duration of follow-up after the end of therapy was 24 weeks. Estimated sustained virologic response (SVR). Comparison of SVR according to the version of virologic response in primary treatment showed that the use of the pilot treatment scheme is most effective at relapse (63%) than in the «null-responders» (33%) and partial (23%) responses to the preceding treatment. In the present study did not reveal a single case of serious adverse events or unexpected adverse events. Thus, the inclusion of proven safety of recombinant IL-1β in the scheme of antiviral therapy in combination with standard interferon-α and ribavirin in patients with chronic hepatitis C, and demonstrated the effectiveness of using recombinant IL-1β (in combination with standard interferon-α and ribavirin), especially in patients with recurrent HCV-infection. |
| first_indexed | 2024-03-12T03:13:40Z |
| format | Article |
| id | doaj.art-e9cdfd986a8149cf8b5d4def697cb2d1 |
| institution | Directory Open Access Journal |
| issn | 2072-6732 |
| language | Russian |
| last_indexed | 2024-03-12T03:13:40Z |
| publishDate | 2014-09-01 |
| publisher | Journal Infectology |
| record_format | Article |
| series | Журнал инфектологии |
| spelling | doaj.art-e9cdfd986a8149cf8b5d4def697cb2d12023-09-03T14:15:28ZrusJournal InfectologyЖурнал инфектологии2072-67322014-09-0144808910.22625/2072-6732-2012-4-4-80-89151Efficacy and safety of triple therapy with recombinant interleukin-1β, recombinant interferon-α and ribavirin in patients with chronic hepatitis C, genotype 1 infection, the non-responders to previous treatment with interferon and ribavirinYu. V. Lobzin0K. V. Zhdanov1A. S. Simbirtsev2A. A. Yakovlev3S. N. Kizhlo4V. H. Fazilov5S. N. Zharov6M. F. Lebedev7Научно-исследовательский институт детских инфекций, Санкт-ПетербургВоенно-медицинская академия им. С.М. Кирова, Санкт-ПетербургГосударственный научно-исследовательский институт особо чистых биопрепаратов, Санкт-ПетербургКлиническая инфекционная больница имени С.П. Боткина, Санкт-ПетербургГородской центр по профилактике и борьбе со СПИД и инфекционными заболеваниями, Санкт-ПетербургКазанский государственный медицинский университет, КазаньРоссийский научно-исследовательский медицинский университет им. Н.И. Пирогова, МоскваООО «ИНГИЛС», Санкт-ПетербургTo assess the efficacy and safety of an experimental course of antiviral therapy with recombinant IL-1β in combination with recombinant interferon-α2b and ribavirin in patients with chronic hepatitis C infected with genotype 1 hepatitis C virus in lacking the virologic response to previous dual therapy pegIFN-α or standard IFN-α and ribavirin has been formed by a group of 50 patients. All patients were treated with recombinant IL-1β – 10 subcutaneous injection at a dose of 0.005 mg/kg every other day, the course of 3 weeks, with 5 courses, recombinant IFN-α2b – subcutaneous injections of 3 million IU every other day for 48 weeks. Ribavirin 1000–1200 mg per day (depending on body weight) for 48 weeks. The duration of follow-up after the end of therapy was 24 weeks. Estimated sustained virologic response (SVR). Comparison of SVR according to the version of virologic response in primary treatment showed that the use of the pilot treatment scheme is most effective at relapse (63%) than in the «null-responders» (33%) and partial (23%) responses to the preceding treatment. In the present study did not reveal a single case of serious adverse events or unexpected adverse events. Thus, the inclusion of proven safety of recombinant IL-1β in the scheme of antiviral therapy in combination with standard interferon-α and ribavirin in patients with chronic hepatitis C, and demonstrated the effectiveness of using recombinant IL-1β (in combination with standard interferon-α and ribavirin), especially in patients with recurrent HCV-infection.https://journal.niidi.ru/jofin/article/view/137хронический вирусный гепатит спротивовирусная терапияэффективностьбезопасностьинтерферонил-1β |
| spellingShingle | Yu. V. Lobzin K. V. Zhdanov A. S. Simbirtsev A. A. Yakovlev S. N. Kizhlo V. H. Fazilov S. N. Zharov M. F. Lebedev Efficacy and safety of triple therapy with recombinant interleukin-1β, recombinant interferon-α and ribavirin in patients with chronic hepatitis C, genotype 1 infection, the non-responders to previous treatment with interferon and ribavirin Журнал инфектологии хронический вирусный гепатит с противовирусная терапия эффективность безопасность интерферон ил-1β |
| title | Efficacy and safety of triple therapy with recombinant interleukin-1β, recombinant interferon-α and ribavirin in patients with chronic hepatitis C, genotype 1 infection, the non-responders to previous treatment with interferon and ribavirin |
| title_full | Efficacy and safety of triple therapy with recombinant interleukin-1β, recombinant interferon-α and ribavirin in patients with chronic hepatitis C, genotype 1 infection, the non-responders to previous treatment with interferon and ribavirin |
| title_fullStr | Efficacy and safety of triple therapy with recombinant interleukin-1β, recombinant interferon-α and ribavirin in patients with chronic hepatitis C, genotype 1 infection, the non-responders to previous treatment with interferon and ribavirin |
| title_full_unstemmed | Efficacy and safety of triple therapy with recombinant interleukin-1β, recombinant interferon-α and ribavirin in patients with chronic hepatitis C, genotype 1 infection, the non-responders to previous treatment with interferon and ribavirin |
| title_short | Efficacy and safety of triple therapy with recombinant interleukin-1β, recombinant interferon-α and ribavirin in patients with chronic hepatitis C, genotype 1 infection, the non-responders to previous treatment with interferon and ribavirin |
| title_sort | efficacy and safety of triple therapy with recombinant interleukin 1β recombinant interferon α and ribavirin in patients with chronic hepatitis c genotype 1 infection the non responders to previous treatment with interferon and ribavirin |
| topic | хронический вирусный гепатит с противовирусная терапия эффективность безопасность интерферон ил-1β |
| url | https://journal.niidi.ru/jofin/article/view/137 |
| work_keys_str_mv | AT yuvlobzin efficacyandsafetyoftripletherapywithrecombinantinterleukin1brecombinantinterferonaandribavirininpatientswithchronichepatitiscgenotype1infectionthenonresponderstoprevioustreatmentwithinterferonandribavirin AT kvzhdanov efficacyandsafetyoftripletherapywithrecombinantinterleukin1brecombinantinterferonaandribavirininpatientswithchronichepatitiscgenotype1infectionthenonresponderstoprevioustreatmentwithinterferonandribavirin AT assimbirtsev efficacyandsafetyoftripletherapywithrecombinantinterleukin1brecombinantinterferonaandribavirininpatientswithchronichepatitiscgenotype1infectionthenonresponderstoprevioustreatmentwithinterferonandribavirin AT aayakovlev efficacyandsafetyoftripletherapywithrecombinantinterleukin1brecombinantinterferonaandribavirininpatientswithchronichepatitiscgenotype1infectionthenonresponderstoprevioustreatmentwithinterferonandribavirin AT snkizhlo efficacyandsafetyoftripletherapywithrecombinantinterleukin1brecombinantinterferonaandribavirininpatientswithchronichepatitiscgenotype1infectionthenonresponderstoprevioustreatmentwithinterferonandribavirin AT vhfazilov efficacyandsafetyoftripletherapywithrecombinantinterleukin1brecombinantinterferonaandribavirininpatientswithchronichepatitiscgenotype1infectionthenonresponderstoprevioustreatmentwithinterferonandribavirin AT snzharov efficacyandsafetyoftripletherapywithrecombinantinterleukin1brecombinantinterferonaandribavirininpatientswithchronichepatitiscgenotype1infectionthenonresponderstoprevioustreatmentwithinterferonandribavirin AT mflebedev efficacyandsafetyoftripletherapywithrecombinantinterleukin1brecombinantinterferonaandribavirininpatientswithchronichepatitiscgenotype1infectionthenonresponderstoprevioustreatmentwithinterferonandribavirin |